Medtech’s first-check shortage and what founders can do about it

You are partway through a pitch and the meeting is going well. Then the investor asks for your regulatory pathway and the milestones between today and an FDA decision, with a timeline and a cost for each.

First checks are getting harder to find, and the investors still writing them often prefer companies that have already reduced technical, regulatory or clinical risk. How you answer can show them how much of that risk is already behind you.

The answer to a tight market may not be a bigger round. It may be a clearer plan, a reshuffling of priorities and a deeper look at your network. Below, we walk through what each hurdle costs, where early money is going, how to build a plan an investor can test and where proof can come from besides capital.

The bill arrives before the revenue

Before a medtech startup earns revenue, it needs answers to four questions. They are often the same four an investor will press on:

  1. Does the device work on the bench?
  2. Does it work in patients?
  3. Will FDA allow it?
  4. Will anyone pay for it?

Each answer takes time, and each costs money.

Measured from concept to FDA decision, a 2022 survey by BCG and UCLA Biodesign found a median of about 31 months for a 510(k), which is generally the pathway for devices similar to ones already on the market. A De Novo, generally for novel lower-risk devices, took about 66 months. For a PMA, generally used for the highest-risk devices, one estimate built from a model prepared for HHS comes to roughly 13 years.

In the same survey, median spending was $3.1 million for a 510(k) and $5 million for a De Novo. A 2010 Stanford study put a PMA at about $94 million on average in 2010 dollars.

While your own device may need less time and money than these figures, your plan still needs to show which hurdle each dollar clears and how long that may take. That breakdown is what an investor is asking for when they ask for your pathway and milestones.

First checks are getting scarcer

Early money is thinning faster than later money. J.P. Morgan’s medtech venture reports show seed and Series A rounds, typically the earliest venture rounds, falling 34% from 2024 to 2025, while later-stage rounds fell 14%. The dollars are also concentrating. Rounds of $50 million or more took 71% of 2025 funding.

The funders behind those checks have changed, too. Venture firms focused on healthcare raised about $7 billion in new funds in 2025, down from $41 billion in 2021. Capital pooling in fewer, larger funds built for bigger, later checks may leave a gap for companies raising under $20 million.

For you, fewer first checks can mean closer diligence on each one, meaning the review an investor does before committing. A regulatory plan that holds up under that review may be what sets your company apart.

Other types of investors are worth a look. Angel Capital Association member groups directed nearly 47% of their 2025 dollars to healthcare broadly, including devices, up from 31% in 2023. Family offices took part in about 31% of startup investments across all sectors, most often as part of a syndicate, meaning a group of investors sharing one deal.

Before you pitch, check each fund’s typical check size against what you are raising, and add angel groups, family offices and strategic investors to your target list. For more fundraising advice, check out our “Stop pitching, start selling” article.

Build a plan an investor can test

A plan an investor can test ties your spending, your team and your timeline to the milestones ahead. Three habits can help: sequencing spending, building lean and planning for surprises.

Sequence spending so each dollar moves you toward the milestone your next round depends on. Before you spend, you should be able to name what investor question it answers.

If your product is software, the first question may come before any pathway: is it a device at all? An investor or a hospital buyer can ask it in writing, and a plain answer on what you can sell and claim today becomes the first milestone to plan for.

Building lean can mean bringing in part-time regulatory, quality or project management expertise for the specific work ahead instead of making full-time hires before you know the workload. Look for help that owns the regulatory plan and its dates, not only advice you are left to carry out alone. A full-time hire can make more sense once that work is steady.

Given significant transitions at the FDA, build in extra time for reviews and feedback and consider a backup path into the regulatory timeline. Ask whoever leads your regulatory work, or peers with a recent review behind them, about their latest experience so your runway covers unplanned delays.

Look for proof beyond capital

Some of the most useful proof for an investor is not capital at all. Strategic partnerships, data licensing, advice from key opinion leaders (respected clinicians in your field) and clinical trial site support can help a young company reduce risk and show commercial traction. Each is evidence that there is demand in the marketplace for what you are building.

Payers and providers also shape how a device is valued and adopted. Ask them what they would need to see to say yes to your innovation. Their views may shape your reimbursement and adoption plan long before launch. If you have no health system contact yet, consider making it one of the first asks of a clinical advisor in your network.

Your regulatory plan is part of the pitch

In a tight market, a regulatory and milestone plan you can defend may carry as much weight with an investor as the deck. The clock starts at concept, the bill builds before revenue and early rounds are fewer than they were a few years ago.

It can be tempting to wait until the round closes before building that plan. That order can work against you, since the plan is often part of what the round is waiting on.

Founders who map the hurdles, name the milestone each round depends on and recruit partners early may have more choices when first checks are scarce.

Reach out to talk through how we can help your team build a flight plan investors can follow.

FAQ

How long does it take to get a medical device to market?

It depends on the regulatory pathway and the device. A 2022 survey of medtech companies found a median of about 31 months from concept to FDA decision for a 510(k) and about 66 months for a De Novo. Complex PMA devices may take considerably longer, and reimbursement and adoption add time after an FDA decision.

How much does it cost to develop a medical device?

Costs vary widely by pathway, device complexity and the amount of clinical evidence needed. A 2022 survey of medtech companies found average costs of $6.1 million for a 510(k) and $17.8 million for a De Novo, with lower medians. Older estimates put PMA devices in the tens of millions of dollars.

Why is it harder for medtech startups to raise seed funding?

Medtech development is slow and capital intensive, and investors often prefer companies that have already reduced technical, regulatory or clinical risk. When fewer small funds are raising capital, fewer first checks may be available for companies earlier in development. A clear regulatory and milestone plan can show that progress.

What funding sources exist besides venture capital?

Founders may look to angel investors, family offices, strategic investors, grants and other non-dilutive funding, meaning money that does not take equity, such as government programs or pitch contests. Each source comes with different timelines, expectations and trade-offs in cost, control and speed.

What is a milestone-based funding plan for a medtech startup?

A milestone-based plan ties each round of funding to the specific achievement that makes the company more valuable to the next investor, such as a completed verification test, a pre-submission meeting with FDA or a pilot agreement. Spending that does not support that milestone can often wait.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *